Citation Impact
Citing Papers
Normal gut microbiota modulates brain development and behavior
2011 Standout
Deep Brain Stimulation for Treatment-Resistant Depression
2005 Standout
Report of the Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder 2000
2002
Current Status of Augmentation and Combination Treatments for Major Depressive Disorder: A Literature Review and a Proposal for a Novel Approach to Improve Practice
2006
Research issues in the study of difficult-to-treat depression
2003
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and Continuation Treatment of Major Depressive Disorder
2002
Medication Augmentation after the Failure of SSRIs for Depression
2006 Standout
Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
2006 Standout
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder
2020 Standout
The Medical Management of Depression
2005
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care
2007
Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application
2006
Cognitive Function Across Manic or Hypomanic, Depressed, and Euthymic States in Bipolar Disorder
2004 Standout
Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics
2003
Depression
2018 Standout
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
2006 Standout
Augmentation of Antidepressants with Atypical Antipsychotics: A Review of the Current Literature
2008
Major depressive disorder
2016 Standout
Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants
2021 Standout
Olanzapine in the Treatment of Refractory Migraine and Chronic Daily Headache
2002
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders
2015
Obesity, serious mental illness and antipsychotic drugs
2009
Costs of Bipolar Disorder
2003
Differential effects of adjunctive methylphenidate and citalopram on extracellular levels of serotonin, noradrenaline and dopamine in the rat brain
2007
Olanzapine Treatment of Psychotic and Behavioral Symptoms in Patients With Alzheimer Disease in Nursing Care Facilities
2000
A Double-Blind Randomized Pilot Study Comparing Quetiapine and Divalproex for Adolescent Mania
2006
Antipsychotic agents in the treatment of bipolar mania
2009
Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat
2004
Pharmacology of antidepressants
2001
Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication
2007 Standout
Physiology and Neurobiology of Stress and Adaptation: Central Role of the Brain
2007 Standout
Prevalence of Neuropsychiatric Symptoms in Dementia and Mild Cognitive Impairment
2002 Standout
In Vivo Modulation of the Activity of Pyramidal Neurons in the Rat Medial Prefrontal Cortex by 5-HT2A Receptors: Relationship to Thalamocortical Afferents
2003
Network pharmacology: the next paradigm in drug discovery
2008 Standout
Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis
2015
Psychedelics
2016 Standout
A Double-Blind, Randomized, Placebo-Controlled Study of Quetiapine as Adjunctive Treatment for Adolescent Mania
2002
What Happened to Lithium? Antidepressant Augmentation in Clinical Settings
2006
The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues
2002
Is preadolescent mania the same condition as adult mania? A British perspective
2003
What Is a “Mood Stabilizer”? An Evidence-Based Response
2004
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
2013 Standout
National Trends in the Outpatient Treatment of Children and Adolescents With Antipsychotic Drugs
2006
The Physiology, Signaling, and Pharmacology of Dopamine Receptors
2011 Standout
The Clinical Global Impression–Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia
2003
A β-arrestin 2 Signaling Complex Mediates Lithium Action on Behavior
2008 StandoutNobel
The economic cost of brain disorders in Europe
2011 Standout
Alzheimer's disease
2006 Standout
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis
2009 Standout
Evaluation of the antidepressant activity of Moringa oleifera alone and in combination with fluoxetine
2015 Standout
Major Depressive Disorder
2008 Standout
Mental health of young people: a global public-health challenge
2007 Standout
Consensus Statement on Management of Intersex Disorders
2006 Standout
Comparing Tolerability of Olanzapine in Schizophrenia and Affective Disorders
2012
Utility of Atypical Antipsychotics in the Treatment of Resistant Unipolar Depression
2009
Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain‐derived neurotrophic factor, β‐catenin and antidepressant‐like effects
2011
Algorithms and Collaborative-care Systems for Depression: Are They Effective and Why?
2006
Alzheimer's Disease
2004 Standout
Pharmacotherapy of Children and Adolescents with Bipolar Disorder
2005
AGA technical review on irritable bowel syndrome
2002 Standout
Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression
2003
Safety of Available Agents Used to Treat Bipolar Disorder
2003
A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder
2004
Adherence to Medication
2005 Standout
The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000.
2000
The clinical global impressions scale: applying a research tool in clinical practice.
2007 Standout
Risperidone versus typical antipsychotic medication for schizophrenia
2003
Pharmacological interventions for somatoform disorders in adults
2014 Standout
Practice parameter: Management of dementia (an evidence-based review) [RETIRED]
2001 Standout
Prevalence and management of treatment-resistant depression.
2007
A fuzzy cognitive map of the psychosocial determinants of obesity
2012 Standout
What Happened to Lithium? Antidepressant Augmentation in Clinical Settings
2006
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
2011 Standout
A systematic review of atypical antipsychotic drugs in schizophrenia
2003
Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
2008 Standout
Clinical Implications of Antipsychotic-Induced Hyperprolactinemia in Patients With Schizophrenia Spectrum or Bipolar Spectrum Disorders
2007
Reported Methodologic Quality and Discrepancies between Large and Small Randomized Trials in Meta-Analyses
2001 Standout
Industry sponsorship and research outcome
2017 Standout
Guideline Watch: Practice Guideline for the Treatment of Patients With Major Depressive Disorder, 2nd Edition
2005
Systematic reviews: CRD's guidance for undertaking reviews in health care
2010 Standout
Works of T. Jacobs being referenced
Olanzapine Versus Placebo in the Treatment of Acute Mania
1999
A Prospective Open-Label Treatment Trial of Olanzapine Monotherapy in Children and Adolescents with Bipolar Disorder
2001
Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling
2002
A Novel Augmentation Strategy for Treating Resistant Major Depression
2001
Olanzapine: Acute and long-term efficacy in bipolar I patients
2000
Is olanzapine a mood-stabilizer?
2000
P.1.092 Olanzapine versus lithium in relapse prevention in bipolar disorder: A randomized double-blind controlled 12-month clinical trial
2003
Long-term olanzapine treatment: Efficacy and safety in manic patients with and without psychotic features
1999
Onset of action of antipsychotics in the treatment of mania
2000
The study of olanzapine plus fluoxetine in treatment-resistant major depressive disorder without psychotic features
2000
Olanzapine plus fluoxetine: Double-blind and open-label results in treatment-resistant major depressive disorder
1999
Olanzapine in the treatment of mania: A placebo-controlled four-week study
1999
Olanzapine vs. placebo in rapid-cycling bipolar disorder
1998